Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160

Rojan Shrestha; Sarah C. Garrett-Thomson; Weifeng Liu; Steven C. Almo; Andras Fiser

doi:10.1016/j.str.2020.07.013

Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160

Rojan Shrestha, Sarah C. Garrett-Thomson, Weifeng Liu, Steven C. Almo, Andras Fiser

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Shrestha et al. use a residue-based pharmacophore as a computational approach to design mutations for the interface of HVEM to make it selective to one or two of its three cognate ligands. In cell assay experiments, 15 of the 25 designed single and double point mutants proved to introduce statistically significant selectivity.

Original language	English (US)
Pages (from-to)	1197-1205.e2
Journal	Structure
Volume	28
Issue number	11
DOIs	https://doi.org/10.1016/j.str.2020.07.013
State	Published - Nov 3 2020

Keywords

HVEM
ProtLID
computational interface design
immune synapse
protein-based drug discovery
protein-protein interactions
residue-specific pharmacophores
switchable-binding selectivity

ASJC Scopus subject areas

Structural Biology
Molecular Biology

Access to Document

10.1016/j.str.2020.07.013

Cite this

@article{13c82157b5884f63937d7a2174813560,

title = "Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160",

abstract = "Shrestha et al. use a residue-based pharmacophore as a computational approach to design mutations for the interface of HVEM to make it selective to one or two of its three cognate ligands. In cell assay experiments, 15 of the 25 designed single and double point mutants proved to introduce statistically significant selectivity.",

keywords = "HVEM, ProtLID, computational interface design, immune synapse, protein-based drug discovery, protein-protein interactions, residue-specific pharmacophores, switchable-binding selectivity",

author = "Rojan Shrestha and Garrett-Thomson, {Sarah C.} and Weifeng Liu and Almo, {Steven C.} and Andras Fiser",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = nov,

day = "3",

doi = "10.1016/j.str.2020.07.013",

language = "English (US)",

volume = "28",

pages = "1197--1205.e2",

journal = "Structure",

issn = "0969-2126",

publisher = "Cell Press",

number = "11",

}

TY - JOUR

T1 - Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160

AU - Shrestha, Rojan

AU - Garrett-Thomson, Sarah C.

AU - Liu, Weifeng

AU - Almo, Steven C.

AU - Fiser, Andras

PY - 2020/11/3

Y1 - 2020/11/3

N2 - Shrestha et al. use a residue-based pharmacophore as a computational approach to design mutations for the interface of HVEM to make it selective to one or two of its three cognate ligands. In cell assay experiments, 15 of the 25 designed single and double point mutants proved to introduce statistically significant selectivity.

AB - Shrestha et al. use a residue-based pharmacophore as a computational approach to design mutations for the interface of HVEM to make it selective to one or two of its three cognate ligands. In cell assay experiments, 15 of the 25 designed single and double point mutants proved to introduce statistically significant selectivity.

KW - HVEM

KW - ProtLID

KW - computational interface design

KW - immune synapse

KW - protein-based drug discovery

KW - protein-protein interactions

KW - residue-specific pharmacophores

KW - switchable-binding selectivity

UR - http://www.scopus.com/inward/record.url?scp=85090057541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090057541&partnerID=8YFLogxK

U2 - 10.1016/j.str.2020.07.013

DO - 10.1016/j.str.2020.07.013

M3 - Article

C2 - 32795404

AN - SCOPUS:85090057541

SN - 0969-2126

VL - 28

SP - 1197-1205.e2

JO - Structure

JF - Structure

IS - 11

ER -

Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this